Literature DB >> 33595892

Immune checkpoint blockade in renal cell carcinoma.

Phillip M Rappold1, Andrew W Silagy1, Ritesh R Kotecha2, Ari A Hakimi1.   

Abstract

Immune checkpoint blockade (ICB) is the foundation of current first-line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long-lasting remissions. With the expanding arsenal of ICB-based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  biomarkers; cytoreductive nephrectomy; immunotherapy; kidney cancer

Mesh：

Substances：

Year:  2021        PMID： 33595892      PMCID： PMC8364550          DOI： 10.1002/jso.26339

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  85 in total

1.  Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.

Authors:  Boris Gershman; Daniel M Moreira; Stephen A Boorjian; Christine M Lohse; John C Cheville; Brian A Costello; Bradley C Leibovich; R Houston Thompson
Journal:  Eur Urol       Date:  2015-06-01       Impact factor: 20.096

2.  Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases.

Authors:  Sohrab Arora; Akshay Sood; Deepansh Dalela; Hoang J Tang; Amit Patel; Jacob Keeley; Quoc-Dien Trinh; Craig G Rogers; Mani Menon; Firas Abdollah
Journal:  Eur Urol       Date:  2018-11-09       Impact factor: 20.096

Review 3.  Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.

Authors:  Charlene M Mantia; David F McDermott
Journal:  Cancer       Date:  2019-09-18       Impact factor: 6.860

4.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

Review 5.  Renal cell carcinoma.

Authors:  R J Motzer; P Russo; D M Nanus; W J Berg
Journal:  Curr Probl Cancer       Date:  1997 Jul-Aug       Impact factor: 3.187

Review 6.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

Authors:  N J Vogelzang; E R Priest; L Borden
Journal:  J Urol       Date:  1992-10       Impact factor: 7.450

8.  First Comprehensive Companion Diagnostic OK'd.

Authors: 
Journal:  Cancer Discov       Date:  2018-01-16       Impact factor: 39.397

9.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Authors:  Yasin Şenbabaoğlu; Ron S Gejman; Andrew G Winer; Ming Liu; Eliezer M Van Allen; Guillermo de Velasco; Diana Miao; Irina Ostrovnaya; Esther Drill; Augustin Luna; Nils Weinhold; William Lee; Brandon J Manley; Danny N Khalil; Samuel D Kaffenberger; Yingbei Chen; Ludmila Danilova; Martin H Voss; Jonathan A Coleman; Paul Russo; Victor E Reuter; Timothy A Chan; Emily H Cheng; David A Scheinberg; Ming O Li; Toni K Choueiri; James J Hsieh; Chris Sander; A Ari Hakimi
Journal:  Genome Biol       Date:  2016-11-17       Impact factor: 13.583

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962
View more
  4 in total

Review 1.  Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.

Authors:  Sari Khaleel; Andrew Katims; Shivaram Cumarasamy; Shoshana Rosenzweig; Kyrollis Attalla; A Ari Hakimi; Reza Mehrazin
Journal:  Cancers (Basel)       Date:  2022-04-22       Impact factor: 6.575

2.  The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.

Authors:  Zhiyu Xi; Pamela S Jones; Masaaki Mikamoto; Xiaobin Jiang; Alexander T Faje; Chuansheng Nie; Kathryn E Labelle; Yunli Zhou; Karen K Miller; Roy J Soberman; Xun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-21       Impact factor: 5.555

Review 3.  Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.

Authors:  Hye-Won Lee
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

4.  Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.

Authors:  Michael A Gorin; Hiten D Patel; Steven P Rowe; Noah M Hahn; Hans J Hammers; Alice Pons; Bruce J Trock; Phillip M Pierorazio; Thomas R Nirschl; Daniela C Salles; Julie E Stein; Tamara L Lotan; Janis M Taube; Charles G Drake; Mohamad E Allaf
Journal:  Eur Urol Oncol       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.